Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Penphomet

Financiado

PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal...

PEN photoporation for the genetic engineering of therapeutic mesenchymal stromal cells and T cells Adoptive cell therapy has emerged as a promising strategy to treat cancer. It relies on patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs), which are genetically engineered to become better equipped to fig... ver más

28/02/2027

TRINCE

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TRINCE No se ha especificado una descripción o un objeto social para esta compañía.

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-26

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01: EIC Transition Challenge: Full scal... Scope:The scope of the Challenge is the maturation of Micro-Nano-Bio technologies developed in previ...

I+D

Cerrada hace 1 año

0% 100% 100%

3 Participantes

TRINCE

1.93M€ | Lider

FUNDACION INSTITUTO ESTUDIOS...

250.00K€ | Participante

NECSTGEN BV

317.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

inteRNAlizer Efficient, safe, and cost-efficient RNA delivery vehicles fo... 150K€ Cerrado

HSC-CRISPR Transcriptional Engineering of Hematopoietic Stem Cells usin... 1M€ Cerrado

NANO-ENGINE A revolutionary cell programming platform based on the targe... 3M€ Cerrado

CPP2021-008676 FiCAT, desarrollo de una nueva tecnología de ingeniería gené... 384K€ Cerrado

NOVISTEM NOn-VIral gene modified STEM cell therapy 4M€ Cerrado

miRToTALL A microRNA-regulated cell death-inducing gene therapy for T-... 150K€ Cerrado

Duración del proyecto: 36 meses Fecha Inicio: 2024-02-26
Fecha Fin: 2027-02-28

Líder del proyecto

TRINCE No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto Adoptive cell therapy has emerged as a promising strategy to treat cancer. It relies on patient-derived cells, such as T cells and mesenchymal stromal cells (MSCs), which are genetically engineered to become better equipped to fight cancer cells. While ex vivo genetic modification of T cells and MSCs has traditionally been performed with viral vectors, they come with concerns about safety, sustainable production and high development costs. Electroporation is a non-viral alternative transfection technology, but can lead to significant gene expression changes, phenotypic alterations, and decreased therapeutic potency. Recently, photoporation with electrospun photothermal nanofibers (PEN photoporation) was demonstrated to provide a safer alternative with minimal impact on the cell’s functionality and phenotype. The technology makes use of photothermal nanofibers which, upon stimulation with laser light, can transiently permeabilize cells to allow gene-modifying effector molecules to enter the cells. Having been thoroughly demonstrated and validated in a research setting (TRL4), this project aims to bring the PEN photoporation technology to TLR6 by developing hard- and software for automated high-throughput transfections of T cells (>1B cells/h) and MSCs (>10M cells/h). The technology will be extensively tested and validated in the cGMP compliant laboratories of the project partners for the genetic engineering of T cells and MSCs. At the same time, steps will be taken to prepare for commercialization and market deployment. By the end of the project a fully automated and validated high-throughput prototype system will be available for installation at centralized cell production facilities or ready for integration in point-of-care cell manufacturing equipment. This project aligns with the Micro-Nano-Bio challenge as it combines nanotechnology with microfluidics to enhance genetically engineered cell therapy products.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores